title: The Brugada syndrome revisited.
abstract: The Brugada syndrome is a rare but well-defined cause of sudden cardiac death. The key underlying abnormality is a decrease in net depolarising current due to a genetic defect, though recent evidence also implicates structural abnormalities in some patients. Diagnosis requires a Brugada-type ECG as well as typical clinical features: such clinical considerations are currently key in guiding risk stratification and hence management. Whilst pharmacological therapies are under investigation, the only intervention with a robust evidence base remains insertion of an implantable cardioverter defibrillator. Further research will be required to allow more effective risk stratification and hence more rational therapy.
authors: Downing College, Cambridge, UK.
authors: Meghavi
authors: M
authors: Mashar
authors: Downing College, Cambridge, UK.
authors: Andrew J
authors: AJ
authors: Kwok
authors: School of Public Health, Imperial College London, London, UK.
authors: Richard
authors: R
authors: Pinder
authors: Downing College, Cambridge, UK; Physiological Laboratory, Rayne Institute, University of Cambridge, St. Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK. Electronic address: ins20@cam.ac.uk.
authors: Ian
authors: I
authors: Sabir
mesh_terms: D053840:Brugada Syndrome / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D002317:Cardiovascular Agents / Q000627:therapeutic use; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control; D017147:Defibrillators, Implantable; D004554:Electric Countershock / Q000295:instrumentation; D004562:Electrocardiography; D006329:Heart Conduction System / Q000503:physiopathology; D006339:Heart Rate; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents